Dihexa for Tinnitus, Hyperacusis & Cochlear Synaptopathy: BDNF, Lenire, Susan Shore Auricle, Maladaptive Auditory Plasticity & the 2026 UK Review

Around 7.6 million UK adults — roughly one in seven — live with persistent tinnitus, and about 1.5 million find it severely affects their quality of life, on Tinnitus UK (the British Tinnitus Association) and RNID figures aligned with the NICE NG155 (March 2020) tinnitus guideline. 2025-2026 has been an unusually active period in the field. In February 2026 the American Journal of Audiology published a peer-reviewed real-world evaluation of Lenire — the bimodal neuromodulation device from Neuromod Devices (Dublin) — reporting that 81.8% of patients with bothersome tinnitus had a clinically significant reduction after 12 weeks, consolidating the device’s March 2023 FDA De Novo authorisation. Susan Shore’s University of Michigan group / Auricle Inc signal-timing device published its randomised trial in somatic tinnitus in JAMA Network Open in 2023 and was still working toward FDA clearance in early 2026. The July 2025 Frontiers in Neuroscience review by Lopes and colleagues consolidated a decade of evidence that Brain-Derived Neurotrophic Factor (BDNF) is a central regulator of the maladaptive auditory plasticity that drives tinnitus — and the same growth-factor / synaptogenic biology Dihexa acts on through the HGF/c-Met axis. The 2025 Wang et al. Advanced Science review of noise-induced cochlear synaptopathy updated the foundational Kujawa & Liberman 2009 hidden-hearing-loss paradigm. Against this backdrop, does Dihexa, the synaptogenic HGF/c-Met-activating peptide, have anything to offer the UK’s 7.6 million tinnitus sufferers? This rigorous 2026 UK review covers what is actually known, what is speculation, and where the evidence is genuinely absent. Readers may also want to read the closely related Dihexa for TBI, Concussion & Stroke Recovery review (head injury is the second-most-common tinnitus precipitant after noise exposure), the Dihexa for Anxiety & Chronic Stress review (the dominant tinnitus-distress driver), the Dihexa, Sleep & Memory Consolidation review (sleep disruption is the second-most-common tinnitus complication) and the Dihexa for Depression & Mood review (severe tinnitus has well-documented bidirectional links with major depression).

Tinnitus in the UK in 2026: Scale, Definitions & Why It Matters

Tinnitus — the perception of sound in the absence of any external acoustic source — is one of the most common chronic conditions in adult medicine. The Tinnitus UK (British Tinnitus Association) and RNID position is that roughly one in seven UK adults (about 7.6 million people) experience persistent tinnitus, with around 1.5 million severely impacted on their daily functioning — sleep, mood, concentration, work, and relationships. The condition disproportionately affects older adults, people with hearing loss, musicians, military veterans, factory and construction workers, and survivors of head injury. The 10-15% adult prevalence figure cited in academic sources (iatrox guideline review, 2026) is consistent with the Tinnitus UK national figure. Around 0.5% of all adults — roughly 270,000 people in England alone — report tinnitus that severely interferes with their ability to live a normal life.

The clinical classification recognised in NICE NG155 distinguishes:

• Subjective tinnitus — perception with no external sound source, by far the most common form, encompassing >99% of cases.
• Objective tinnitus — a sound source the examiner can also hear, typically vascular (pulsatile, in time with the heartbeat) or muscular (myoclonus). Pulsatile tinnitus is a red flag that warrants imaging.
• Primary tinnitus — idiopathic, often associated with sensorineural hearing loss.
• Secondary tinnitus — identifiable cause (Ménière’s disease, otosclerosis, acoustic neuroma, ototoxic medication, head injury, temporomandibular joint dysfunction).
• Somatic tinnitus — the subset where head, neck or jaw movement modulates the tinnitus percept, accounting for around 60-80% of cases by some series. This is the subgroup targeted by the Susan Shore / Auricle device.

Hyperacusis — the perception of normal environmental sound as uncomfortably or painfully loud — affects around 2% of UK adults and overlaps substantially with tinnitus. Hyperacusis subdivides into loudness hyperacusis (a generic intolerance), annoyance hyperacusis, fear hyperacusis (phonophobia), and pain hyperacusis (pain at moderate sound levels, the most disabling subtype, which a 2025 Hyperacusis Research consortium consensus statement formally separated from loudness hyperacusis as a distinct clinical entity). Misophonia — an emotionally aversive response to specific 'trigger' sounds (chewing, breathing, repetitive tapping) — is mechanistically distinct from hyperacusis (more limbic, less auditory) and is increasingly recognised as a separate condition.

Cochlear synaptopathy or hidden hearing loss is the most consequential mechanistic concept added to the field in the last 15 years — the noise-induced loss of inner-hair-cell ribbon synapses with no change to the pure-tone audiogram. Sufferers report difficulty understanding speech in noisy environments despite “normal” hearing tests, and the condition is now the leading mechanistic candidate for the large population of tinnitus patients with normal audiograms. We return to this in detail below.

The Modern Mechanistic Picture: From Cochlear Insult to Central Phantom Percept

The dominant explanatory framework for tinnitus in 2026 is central neural plasticity following peripheral cochlear injury. The story has three components: the peripheral trigger, the central response, and the maladaptive consolidation that turns a transient response into a chronic disease state.

Step 1: The Peripheral Trigger

Most tinnitus follows some form of cochlear injury — noise exposure (the single largest cause), age-related hearing loss (presbycusis), ototoxic medication (cisplatin, aminoglycoside antibiotics, loop diuretics, high-dose aspirin), Ménière’s disease, otosclerosis, sudden sensorineural hearing loss, head injury, or acoustic neuroma. The peripheral insult can manifest as overt hearing loss on the pure-tone audiogram, or, increasingly recognised, as cochlear synaptopathy — loss of the ribbon synapses connecting inner hair cells to spiral ganglion neurons — with no change to threshold audiometry.

Kujawa and Liberman’s landmark 2009 Journal of Neuroscience paper at Massachusetts Eye and Ear demonstrated in CBA/CaJ mice that a noise exposure producing a fully recoverable temporary threshold shift — the kind that produces no detectable lasting audiogram change — nevertheless destroyed roughly 50% of inner-hair-cell ribbon synapses, with corresponding permanent reduction in auditory brainstem response (ABR) wave I amplitude. The hair cells survived; the synapses didn’t. The 2025 Wang et al. Advanced Science review consolidated 16 years of follow-up: cochlear synaptopathy is the most plausible mechanism for the discrepancy between “normal” audiograms and the disabling speech-in-noise difficulties of musicians, teachers, factory workers and military veterans — and is one of the most likely peripheral triggers for tinnitus in the so-called “normal hearing” population.

The biology is selective: it is preferentially the low-spontaneous-rate, high-threshold auditory nerve fibres that are lost. These fibres encode loud sounds against background noise — explaining why patients can hear pure tones in a quiet booth but lose speech in a crowded restaurant. Spiral ganglion neurons that lose their inner-hair-cell synapse eventually undergo retrograde degeneration over years to decades.

Step 2: The Central Response — Disinhibition and Central Gain

Reduced peripheral input drives compensatory increases in central auditory gain. The dorsal cochlear nucleus (DCN), inferior colliculus (IC) and auditory cortex (A1) all increase intrinsic neuronal excitability, reduce inhibitory GABAergic and glycinergic tone, and reorganise tonotopic maps — with regions formerly tuned to lost frequencies adopting nearby frequencies (the “edge-frequency” shift). In the dorsal cochlear nucleus the principal fusiform cells fire spontaneously at elevated rates, with abnormal bursting and synchrony. In the auditory cortex, tonotopic reorganisation around the hearing-loss edge and increased pyramidal-cell firing rates correlate with the perceptual tinnitus pitch.

This is the central gain hypothesis — an extension of the homeostatic plasticity framework that the brain uses to maintain stable activity levels in the face of changing input. When the input drops, the gain comes up. Functionally adaptive in the short term, persistently maladaptive in the long term, because the elevated gain manifests as a phantom signal: tinnitus.

Step 3: BDNF & the Synaptic Plasticity Machinery

The July 2025 Frontiers in Neuroscience review by Lopes and colleagues — the most comprehensive recent synthesis — consolidates the role of Brain-Derived Neurotrophic Factor (BDNF) in tinnitus pathogenesis. Three lines of evidence converge:

1. Animal models: in noise-induced tinnitus, BDNF expression and TrkB receptor signalling in the cochlear nucleus, auditory cortex and limbic system are reorganised, with regional up- and down-regulation that tracks the development of the tinnitus phenotype. BDNF supports the synaptic plasticity that both produces the maladaptive central gain and could theoretically be harnessed to reverse it.
2. Spiral ganglion neuron survival: the foundational spiral ganglion neuron synaptic transmission work shows that BDNF/NT-3 supply from hair cells is essential for ribbon-synapse maintenance; cochlear synaptopathy involves loss of this trophic support.
3. Human genetics: the BDNF Val66Met polymorphism, which reduces activity-dependent BDNF secretion, has been associated with tinnitus susceptibility in several cohort studies, although replication has been inconsistent.

This is the explicit mechanistic anchor for any putative synaptogenic intervention. Dihexa engages the HGF/c-Met pathway, which converges on BDNF expression and TrkB-dependent synaptogenesis (Benoist et al., 2014, JPET). The mechanistic case for a peptide intervention is therefore not absurd — but it is unproven and the directionality is uncertain. We return to this in section 5.

Step 4: The Limbic Distress Network

The intensity of tinnitus is anatomically separable from the distress it causes. The Jastreboff neurophysiological model places auditory pathways as the percept generator and the limbic system — amygdala, anterior cingulate, insula, ventromedial prefrontal cortex — as the distress amplifier. Two patients with identical tinnitus loudness can have completely different functional impact depending on limbic engagement. This is why cognitive behavioural therapy (CBT) for tinnitus is the most evidence-based intervention in the NICE NG155 pathway: it doesn’t change the tinnitus percept, it changes its limbic and attentional impact. It is also why the Dihexa for Anxiety & Stress and Dihexa for Depression & Mood reviews are directly relevant: tinnitus distress is a mood/anxiety condition layered on top of an auditory phenomenon.

The 2026 UK Treatment Landscape: NICE NG155, Lenire, Auricle, CBT, Sound Therapy

UK tinnitus management is anchored by NICE NG155 (Tinnitus: assessment and management, March 2020). The guideline sets the pathway: GP-led initial assessment with red-flag triage; audiology assessment for hearing loss; provision of psychological support with CBT first-line for tinnitus distress; consideration of sound therapy and hearing aids if indicated; tinnitus retraining therapy (TRT) for selected patients; and the explicit recommendation against routine pharmacological treatment because no drug has demonstrated efficacy.

NICE NG155 Red Flags Requiring Urgent ENT Referral

• Sudden sensorineural hearing loss within the last 72 hours (this is a medical emergency — oral corticosteroids within 72 hours improve recovery odds).
• Unilateral (one-sided) tinnitus with no clear cause — warrants MRI to exclude acoustic neuroma (vestibular schwannoma).
• Pulsatile tinnitus that beats in time with the heartbeat — warrants imaging to exclude vascular causes (carotid stenosis, arteriovenous malformation, dural arteriovenous fistula, idiopathic intracranial hypertension).
• Focal neurological signs.
• Persistent severe distress with suicidal thinking — tinnitus has well-documented bidirectional links with major depression and suicide risk; severe distress requires same-day mental-health pathway.
• Tinnitus following head injury (especially if accompanied by vertigo or imbalance) — warrants specialist assessment.

Lenire Bimodal Neuromodulation (Neuromod Devices, Dublin)

Lenire is the only neuromodulation device for tinnitus with regulatory clearance available to UK patients in 2026. It combines:

• Sound therapy delivered through Bluetooth headphones — customised soundscapes designed to provide broad-spectrum auditory stimulation.
• Mild electrical stimulation of the tongue via the Tonguetip® intra-oral device, providing somatosensory input that synchronises with the auditory stimulation.

The biological rationale is that paired auditory-somatosensory stimulation drives spike-timing-dependent plasticity in the dorsal cochlear nucleus and inferior colliculus, normalising the abnormal synchrony and gain that maintain the phantom percept.

Lenire received its FDA De Novo authorisation in March 2023 on the back of the controlled TENT-A3 trial (multi-site single-arm controlled pivotal trial of combined sound with tongue stimulation). It is CE-marked in Europe and is available through certified audiology providers in the UK and Ireland.

The February 2026 American Journal of Audiology peer-reviewed real-world evaluation — the second such study — reported that among patients with bothersome tinnitus on the Tinnitus Functional Index (TFI), 81.8% achieved a clinically significant reduction (defined as a TFI decrease ≥13 points) after 12 weeks of Lenire treatment in US clinical practice. A retrospective chart review across multiple US sites supports the consistency of the effect. Neuromod’s February 2026 PR Newswire release confirmed the consistency between the real-world and pivotal-trial data. The US Department of Veterans Affairs has added Lenire to its tinnitus treatment options.

UK availability is on a private-pay basis at typical costs of around £2,500-3,500 for the 12-week treatment course, with providers including The Tinnitus Clinic London and a growing network of audiology partners. The device is not currently NICE-evaluated and is not available on the NHS.

Susan Shore / University of Michigan / Auricle Inc Signal-Timing Device

A separate bimodal neuromodulation device, based on 20 years of research by Susan Shore at the University of Michigan and over $14 million in funding, uses paired precisely timed auditory and somatosensory stimuli to reverse the abnormal synchronisation in the dorsal cochlear nucleus identified in her preclinical work.

The 2023 JAMA Network Open randomised clinical trial by Marks, Martel, Wu, Basura, Roberts, Schvartz-Leyzac and Shore reported that the device reduced tinnitus loudness and TFI scores in patients with somatic tinnitus — the subgroup where head, neck or jaw movement modulates the tinnitus percept. The American Tinnitus Association coverage framed the finding as a meaningful advance.

Shore and David Martel patented the device and co-founded Auricle Inc to commercialise it. As of early 2026 reporting, the device has not received FDA approval, and Auricle has not committed to a public release date. The Tinnitus Hub Q&A with Shore indicates ongoing work toward FDA clearance. A useful real-world comparison piece is this 2026 audiologist write-up on why patients should not wait indefinitely. For UK patients seeking bimodal neuromodulation today, Lenire remains the only commercially available option.

CBT, Sound Therapy & Hearing Aids

The first-line NICE NG155 management for tinnitus-related distress is cognitive behavioural therapy (CBT), with growing evidence for mindfulness-based cognitive therapy (MBCT) as an alternative. NHS Talking Therapies (IAPT) services in some regions deliver tinnitus-specific CBT; in other regions referral to specialist audiology with embedded psychological support is the route. Tinnitus retraining therapy (TRT), based on the Jastreboff neurophysiological model, combines low-level sound therapy with directive counselling and has a longer evidence track record but more variable individual outcomes.

If audiometry demonstrates hearing loss, hearing aids are first-line: providing amplification of the lost frequencies restores cochlear input, reduces central gain, and frequently reduces tinnitus loudness as a side benefit. Many modern hearing aids include integrated tinnitus masking soundscapes that can be tailored to the individual’s tinnitus profile. The NHS provides hearing aids free at the point of care through audiology services.

Other Interventions: rTMS, Cochlear Implants, Off-Label Drugs

Repetitive transcranial magnetic stimulation (rTMS) targeting the auditory cortex has produced modest, inconsistent effects across multiple trials; it is not part of routine NHS care but is available in some research settings. Cochlear implants are highly effective at reducing tinnitus when implanted for severe-to-profound sensorineural hearing loss (NICE TA566 — cochlear implants for severe to profound bilateral deafness in children and adults).

Off-label drug use is common but evidence-light. Tricyclic antidepressants (amitriptyline, nortriptyline) and gabapentin have small RCT signals in selected populations. Benzodiazepines and zopiclone are sometimes used for tinnitus-related sleep disruption but carry dependence risk. Betahistine, often prescribed for Ménière’s-associated tinnitus, has no NICE recommendation for primary tinnitus. No supplement (zinc, ginkgo, melatonin, magnesium) has shown convincing efficacy in randomised trials.

The Inner-Ear Drug-Development Graveyard: Otonomy, Frequency, Decibel

One of the most striking features of the 2026 tinnitus landscape is the spectacular failure of the recent generation of biotech inner-ear drug programmes. The pattern matters because it informs how seriously to take any unproven peptide claim for tinnitus or hearing loss.

Otonomy & the OTO-313 Failure

Otonomy was the leading inner-ear drug-development company of the late 2010s and early 2020s, with a portfolio of intratympanic-injection sustained-release formulations. Its lead tinnitus candidate OTO-313 (intratympanic gacyclidine, a non-competitive NMDA-receptor antagonist intended to block aberrant glutamatergic firing in cochlear nerve terminals) failed its Phase 2 trial in August 2022 — the primary endpoint of tinnitus loudness and TFI reduction did not differ from placebo. The Hearing Tracker coverage of the broader inner-ear drug ecosystem captured the impact. Otonomy wound down operations by December 2022.

Spiral Therapeutics subsequently acquired Otonomy’s preclinical and clinical assets: OTIVIDEX (OTO-104, dexamethasone for Ménière’s); OTO-510 (cisplatin-induced ototoxicity prevention); and the most directly relevant asset, OTO-413 — recombinant BDNF for cochlear synaptopathy. Spiral continues to develop these programmes but timelines have not been publicly committed.

Frequency Therapeutics & FX-322

Frequency Therapeutics’ FX-322 (a small-molecule cocktail of a GSK-3 inhibitor and an HDAC inhibitor, intended to stimulate Lgr5+ cochlear progenitor cells to differentiate into new hair cells via intratympanic injection) was the most-watched hearing-regeneration programme of the early 2020s. The Phase 2a study failed key efficacy endpoints, the company abandoned the hearing-loss programme, and Frequency subsequently merged with Korro Bio. The combined company had ~$170 million in cash with runway through 2026 milestones in different therapeutic areas. The Hearing Tracker coverage documented the wind-down.

Decibel Therapeutics & DB-OTO (Regeneron)

Decibel Therapeutics was acquired by Regeneron in 2023 and continues to develop DB-OTO — an adeno-associated virus (AAV)-based gene therapy delivering a functional copy of the otoferlin gene to children with otoferlin (OTOF) mutations causing profound congenital sensorineural hearing loss. Early data have shown striking hearing restoration in deaf children. This programme is critically important — but it is hearing-loss restoration in a genetically defined paediatric population, not adult tinnitus treatment. The lesson: precision-medicine, genetically defined programmes appear tractable; idiopathic adult tinnitus does not.

The Genetic Engineering & Biotechnology News “Targeting the Inner Ear” overview and DelveInsight pipeline analysis survey the 20+ companies still active in sensorineural hearing loss. Audion Therapeutics has its BB103 (LY3056480, a Notch inhibitor) Phase 1/2 programme in adults with mild-to-moderate hearing loss, with results not yet reported. Active tinnitus clinical trials in 2026 cover repetitive transcranial magnetic stimulation, vagal nerve stimulation, novel cognitive interventions, and several behavioural protocols — but no major late-phase pharmaceutical or peptide programme.

The clinical message: idiopathic adult tinnitus is mechanistically heterogeneous, the available animal models do not robustly predict human efficacy, and even well-resourced biotechs with sophisticated cochlear delivery platforms have failed. This is the context in which any claim that a research-chemical peptide can “treat” tinnitus should be evaluated.

Where Could Dihexa Theoretically Fit in Tinnitus Biology?

To be fair to the mechanistic question, here is the honest case for Dihexa in tinnitus, hyperacusis and cochlear synaptopathy — with realistic confidence levels and directionality concerns:

The Cochlear Delivery Problem

Even if Dihexa had a relevant biological effect, the cochlea is one of the hardest pharmaceutical targets in the body. The blood-labyrinth barrier is tighter than the blood-brain barrier; systemic dosing produces low cochlear concentrations; intratympanic injection (the route used by Otonomy, Spiral, and Frequency Therapeutics) reaches the cochlea via the round window membrane but with substantial inter-patient variability. There is no public data on Dihexa cochlear pharmacokinetics by any route. The Dihexa dosage guide and mechanism of action page cover the systemic pharmacology in detail; cochlear penetration has not been characterised.

The Directionality Problem — Why More Plasticity Is Not Obviously Better

This is the central conceptual concern. In conditions like mild cognitive impairment, post-stroke recovery, multiple sclerosis, or traumatic brain injury, the problem is too little synaptic plasticity — augmenting it is mechanistically aligned with recovery. In tinnitus, the problem is maladaptive plasticity — an active, ongoing, pathological synaptic reorganisation that produces the phantom percept. Pharmacologically augmenting that machinery could reinforce rather than reverse it. The honest answer is that we don’t know which direction the effect would go, and the absence of any human trial means no-one will know for years. This is one of the few conditions on Dihexa.co.uk where the theoretical risk of worsening the condition deserves equal weight with the theoretical benefit.

Fosgonimeton — The Closest HGF-Pathway Clinical Cousin

Fosgonimeton (ATH-1017), developed by Athira Pharma, is the closest small-molecule analogue of Dihexa to have reached human trials — tested in Alzheimer’s disease (the LIFT-AD Phase 2/3 programme), and dementia with Lewy bodies / Parkinson’s disease dementia (the SHAPE Phase 2 study). Mixed results across these programmes; zero programmes in tinnitus, hyperacusis, hearing loss, or any otologic indication. This is the most concrete signal that even the developers of the HGF-enhancer chemical class do not consider hearing loss a credible early indication. The closest peripheral-tissue HGF programme is Helixmith’s Engensis (VM202) plasmid HGF gene therapy, which is in amyotrophic lateral sclerosis and diabetic neuropathy, not hearing loss.

What the Evidence Actually Shows: Honest Assessment

Let’s be specific about what does and doesn’t exist.

Evidence Supporting a Synaptogenic Peptide in Tinnitus

• The July 2025 Frontiers in Neuroscience BDNF-in-tinnitus review consolidates BDNF as a central regulator of tinnitus pathogenesis.
• Animal models show that exogenous BDNF protects ribbon synapses against noise damage and can promote their regeneration.
• Cochlear synaptopathy is a clearly defined, measurable peripheral lesion that a synaptogenic agent could in principle reverse.
• HGF/c-Met activation has demonstrated trophic effects on multiple neuronal populations in vivo (Wright laboratory work, research and studies overview).

Evidence Against (or Absent For) Dihexa in Tinnitus

• Zero human clinical trials of Dihexa in any tinnitus, hyperacusis or hearing-loss population.
• Zero programmes from the developers of the HGF-enhancer chemical class in any otologic indication.
• Spiral Therapeutics’ OTO-413 — recombinant BDNF itself — has not yet reported positive Phase 2 efficacy.
• Frequency Therapeutics’ FX-322 failure shows that even mechanistically targeted intratympanic interventions are hard.
• The maladaptive plasticity / directionality concern (above).
• No characterised cochlear pharmacokinetics by any Dihexa route.
• The Otonomy / Frequency / general inner-ear drug failures show that the field broadly is much harder than mechanistic case-making suggests.

Net assessment: biologically interesting on at least two of five axes (cochlear synaptopathy, limbic distress), actively concerning on one (central gain directionality), completely untested clinically, and strongly subordinate to the evidence-based NICE NG155 pathway (hearing aids, CBT, sound therapy) plus the only regulatorily authorised device-based intervention (Lenire bimodal neuromodulation).

Related Tinnitus-Adjacent Conditions Where Dihexa Reviews Already Exist

Several conditions on the site share biology with tinnitus and are worth reviewing alongside:

• Dihexa for TBI, Concussion & Post-Concussion Syndrome — head injury is the second-most-common tinnitus precipitant after noise exposure; post-traumatic tinnitus is a frequent component of post-concussion syndrome.
• Dihexa for Anxiety & Chronic Stress — the dominant tinnitus-distress driver and the principal target of CBT for tinnitus.
• Dihexa for Depression & Mood — severe tinnitus has bidirectional links with major depression and increased suicide risk.
• Dihexa, Sleep & Memory Consolidation — sleep disruption is the most common functional impact of tinnitus.
• Dihexa for MCI & Brain Aging — the 2024 Lancet Commission formally added uncorrected hearing loss as a modifiable dementia risk factor accounting for ~7-8% of preventable cases.
• Dihexa for PTSD & Complex PTSD — military blast-exposure tinnitus is the most prevalent service-related condition in UK and US veterans (~50% of recent-deployment veterans).
• Dihexa for Long COVID Brain Fog — new-onset and worsening tinnitus is a documented Long COVID complication, plausibly via microglial neuroinflammation overlap.
• Dihexa for Menopause & Perimenopause Brain Fog — oestrogen withdrawal is associated with new-onset tinnitus in some women.
• Dihexa for Vascular Dementia & VCI — pulsatile tinnitus can be the first symptom of carotid or intracranial vascular disease.

A Practical 2026 UK Pathway for Tinnitus & Hyperacusis

If you have tinnitus, hyperacusis or hearing loss, the evidence-based 2026 UK pathway is:

1. See your GP. Describe duration, laterality (one ear, both ears, in your head), whether it pulses with your heartbeat, any associated hearing loss or vertigo, and any triggering event (loud noise exposure, head injury, viral infection, new medication). Bring your Tinnitus Functional Index score if you have one.
2. Red flags = urgent referral. Sudden hearing loss (within 72 hours), unilateral tinnitus, pulsatile tinnitus, focal neurology, persistent severe distress with suicidal thinking — all warrant same-day or urgent ENT / audiovestibular medicine referral under NICE NG155.
3. Standard pathway = NHS audiology. Pure-tone audiometry, tympanometry, otoacoustic emissions, speech-in-noise testing, tinnitus history, impact assessment. Hearing aids if hearing loss is identified. Some areas offer the British Society of Audiology high-frequency audiometry that can pick up early presbycusis missed by standard audiometry.
4. Psychological support = CBT first-line. Through NHS Talking Therapies (IAPT) where available, or specialist audiology psychology services. Tinnitus UK peer support is invaluable.
5. Sound therapy. Hearing-aid built-in maskers, smartphone apps (ReSound Relief, Oticon ON), or dedicated sound generators.
6. Lenire bimodal neuromodulation for selected patients who can self-fund (~£2,500-3,500) and have moderate or worse tinnitus on the TFI. Currently the only neuromodulation device with regulatory clearance available to UK patients.
7. Lifestyle. Avoid loud noise exposure (or use musicians’ earplugs / custom hearing protection); manage cardiovascular risk factors (the 2024 Lancet Commission list applies); treat sleep disorders; minimise alcohol and caffeine in those who are sensitive; check medications for ototoxicity (NSAIDs in high doses, aminoglycosides, loop diuretics, cisplatin, hydroxychloroquine).
8. Research. NIHR Be Part of Research for tinnitus and hearing-loss studies; the UCL Ear Institute, Cambridge Hearing Group, and the Nottingham Biomedical Research Centre Hearing theme are the principal UK research centres.
9. Crisis support. Tinnitus has clear links to mental-health crisis. Tinnitus UK’s freephone helpline (0800 018 0527), the Samaritans (116 123), and NHS 111 are all appropriate for crisis support.

Bottom Line: Is Dihexa Worth Considering for Tinnitus in 2026?

No — not in the 2026 evidence base, and not with the currently available alternatives.

The mechanistic case is more interesting than for most indications — the BDNF and HGF/c-Met biology is genuinely relevant to tinnitus pathophysiology, and the cochlear-synaptopathy-as-trigger framework provides a clear molecular target. But the directionality concern is real: tinnitus is fundamentally a disorder of maladaptive auditory plasticity, and a peptide that augments synaptogenic plasticity machinery could plausibly worsen it. The complete absence of human trial data means we don’t know which way the effect goes — and won’t for years. The February 2026 Lenire 81.8%-clinically-significant-reduction real-world result is the best available external benchmark; it sets a meaningful bar that any putative peptide intervention would have to exceed in a properly designed trial. None has been or is being conducted.

For UK patients in 2026, the evidence-based pathway is unambiguous: GP referral under NICE NG155, NHS audiology assessment, hearing aids if indicated, CBT for distress, sound therapy, and for selected self-funders the Lenire bimodal neuromodulation device. The Tinnitus UK helpline (0800 018 0527) is the single most useful first contact for anyone newly diagnosed. Self-experimenting with an unscheduled research peptide for a condition where the directionality concern is unresolved is not a defensible 2026 decision.

For a complete picture of where the Dihexa evidence base does and doesn’t exist, see the Dihexa Review 2026 overview, the potential benefits summary, the side effects and risks page, the dosage guide, and the UK legal status page.

Selected References & External Sources

1. NICE NG155 (March 2020). Tinnitus: assessment and management. — nice.org.uk/guidance/ng155
2. Boedts M et al. (2026). Bimodal Neuromodulation for Tinnitus in a Clinical Practice Setting: Clinically Significant Benefit for Patients With Moderate or Worse Symptoms. American Journal of Audiology. — PubMed 41528257
3. Conlon B et al. (2024). Effectiveness of bimodal neuromodulation for tinnitus treatment in a real-world clinical setting in United States: A retrospective chart review. — medRxiv preprint · PMC published version
4. Conlon B et al. (2024). Combining sound with tongue stimulation for the treatment of tinnitus: a multi-site single-arm controlled pivotal trial (TENT-A3). — PMC11333749
5. Neuromod Devices / Lenire February 2026 press release. — PR Newswire
6. Hearing Health & Technology Matters (2026). Lenire shows consistent outcomes for U.S. tinnitus patients in second peer-reviewed real-world study. — Hearing Health Matters
7. Marks KL, Martel DT, Wu C, Basura GJ, Roberts LE, Schvartz-Leyzac KC, Shore SE (2023). Reversing Synchronized Brain Circuits Using Targeted Auditory-Somatosensory Stimulation to Treat Phantom Percepts: A Randomized Clinical Trial. JAMA Network Open. — PMC10238951
8. Lopes JL et al. (2025). Neuroplasticity and tinnitus: the role of Brain-Derived Neurotrophic Factor in pathogenesis and treatment. Frontiers in Neuroscience. — Frontiers · PMC12279856
9. Kujawa SG, Liberman MC (2009). Adding insult to injury: cochlear nerve degeneration after “temporary” noise-induced hearing loss. Journal of Neuroscience. — jneurosci.org
10. Wang J et al. (2025). Consequences and Mechanisms of Noise-Induced Cochlear Synaptopathy and Hidden Hearing Loss, With Focuses on Signal Perception in Noise and Temporal Processing. Advanced Science. — Wiley Online
11. Mertens G et al. (2022). Detecting Noise-Induced Cochlear Synaptopathy by Auditory Brainstem Response in Tinnitus Patients With Normal Hearing Thresholds: A Meta-Analysis. Frontiers in Neuroscience. — PMC8721093
12. Hashir Tinnitus Clinic (2026). Annual Tinnitus Report 2026 (analysis of 446 peer-reviewed studies). — hashirtinnitusclinic.com
13. Yang Y et al. (2023). Candidate Key Proteins in Tinnitus: A Bioinformatic Study of Synaptic Transmission in Spiral Ganglion Neurons. Cellular and Molecular Neurobiology. — Springer
14. Wu X et al. (2020). Protection of Cochlear Ribbon Synapses and Prevention of Hidden Hearing Loss. Neural Plasticity. — PMC7652619
15. Benoist CC et al. (2014). The procognitive and synaptogenic effects of angiotensin IV-derived peptides are dependent on activation of the hepatocyte growth factor/c-Met system. J Pharmacol Exp Ther. — PubMed 24403718
16. Wright JW & Harding JW (2015). The brain hepatocyte growth factor/c-Met receptor system: a new target for the treatment of Alzheimer’s disease. — PubMed 25711386
17. Hearing Tracker (2023). Frequency Therapeutics Abandons Hearing Loss Treatment Programs. — hearingtracker.com
18. Genetic Engineering & Biotechnology News. Targeting the Inner Ear. — genengnews.com
19. GEN (2024). StockWatch: Regeneron’s All Ears for Hearing Loss Drug Developer (Decibel acquisition). — genengnews.com
20. DelveInsight (October 2024). Advancements in Sensorineural Hearing Loss Clinical Trial Pipeline as 20+ Companies Pave the Way for Future Solutions. — GlobeNewswire
21. Clinicaltrials.gov — DB-OTO (Otoferlin Gene Therapy) Study in Children with Otoferlin Mutations. — NCT05788536
22. Tinnitus UK (British Tinnitus Association) — tinnitus.org.uk · Tinnitus UK GP guidance — GP Guidance
23. RNID (Royal National Institute for Deaf People) — rnid.org.uk
24. British Academy of Audiology — NICE NG155 guideline summary. — baaudiology.org
25. Iatrox (2026). Tinnitus: NICE Guidance + Key Steps & Red Flags. — iatrox.com/guidelines/tinnitus
26. UCL Ear Institute — ucl.ac.uk/ear
27. NIHR Be Part of Research portal — bepartofresearch.nihr.ac.uk
28. NICE TA566 — Cochlear implants for severe to profound bilateral deafness. — nice.org.uk/guidance/ta566